ImmunityBio: Anktiva's Launch Demands A Reassessment [Seeking Alpha]
![Seeking Alpha](../../../Content/images/providers/Seeking Alpha.png)
ImmunityBio, Inc. (IBRX)
Company Research
Source: Seeking Alpha
The company is well-prepared for the launch, with a strong sales force, established distribution channels, and sufficient inventory. Analyst projections suggest significant growth for ImmunityBio, with the potential for Anktiva to become a blockbuster drug and drive the company's revenue in the coming years. It has been nearly two years since my last ImmunityBio ( NASDAQ: IBRX article , where I mentioned that the company had just submitted their BLA for Anktiva (N-803) to be used in combination with BCG for "BCG-unresponsive non-muscle invasive bladder Recommended For You Recommended For You About IBRX Stock More on IBRX Related Stocks Trending Analysis Trending News
Show less
Read more
Impact Snapshot
Event Time:
IBRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IBRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IBRX alerts
High impacting ImmunityBio, Inc. news events
Weekly update
A roundup of the hottest topics
IBRX
News
- ImmunityBio (IBRX) Gains 17% in the Past Week: Here's Why [Yahoo! Finance]Yahoo! Finance
- Cancer Kills Millions of Dogs. Will Immunotherapy Prolong Their Lives? [The New York Times]The New York Times
- ImmunityBio Announces Insurance Coverage of ANKTIVA® Across Multiple States with First Commercial Doses Administered Just Weeks After FDA Approval—Opening New Era for Immunotherapy Beyond Checkpoint Inhibitors [Yahoo! Finance]Yahoo! Finance
- ImmunityBio Announces Insurance Coverage of ANKTIVA® Across Multiple States with First Commercial Doses Administered Just Weeks After FDA Approval—Opening New Era for Immunotherapy Beyond Checkpoint InhibitorsBusiness Wire
- ImmunityBio Announces 2024 Annual Meeting of Stockholders with Company Update [Yahoo! Finance]Yahoo! Finance
IBRX
Earnings
- 5/9/24 - Miss
IBRX
Sec Filings
- 6/20/24 - Form S-8
- 6/13/24 - Form 4
- 6/13/24 - Form 4
- IBRX's page on the SEC website